Kindred Biosciences Inc Quick Ratio (KIN) starting from the second quarter 2021 to second quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kindred Biosciences Inc   (NASDAQ: KIN)

Kindred Biosciences Inc 's Quick Ratio

KIN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2021, Quick Ratio fell to 6.59 below Kindred Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 287 other companies have achieved higher Quick Ratio than Kindred Biosciences Inc in second quarter 2021. While Quick Ratio total ranking in the second quarter 2021 has deteriorated compared to the prior quarter from 669 to 912.

Explain Quick Ratio?
How much Cash & cash equivalents KIN´s has?
What are KIN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KIN Quick Ratio (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2
Y / Y Current Liabilities Change 62.04 % -35.73 % -32.55 % -47.28 % -9.02 %
Y / Y Cash & cash equivalent Change 10.55 % 18.14 % -18.59 % -28.71 % -15.66 %
Quick Ratio MRQ 6.59 9.64 8.47 11.69 9.66
KIN's Total Ranking # 912 # 669 # 463 # 324 # 668
Seq. Current Liabilities Change 71.86 % -4.99 % 29.36 % -23.28 % -31.84 %
Seq. Cash & cash equivalent Change 17.49 % 8.18 % -6.35 % -7.12 % 25.56 %



Quick Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 288
Healthcare Sector # 469
Overall Market # 912


Quick Ratio Statistics
High Average Low
44.74 19.86 4.87
(Sep 30 2014)   (Dec 31 2018)




Financial Statements
Kindred Biosciences Inc 's Current Liabilities $ 11 Millions Visit KIN's Balance sheet
Kindred Biosciences Inc 's Cash & cash equivalent $ 74 Millions Visit KIN's Balance sheet
Source of KIN's Sales Visit KIN's Sales by Geography


Cumulative Kindred Biosciences Inc 's Quick Ratio

KIN's Quick Ratio for the trailling 12 Months

KIN Quick Ratio

 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth -19.85 % -32.59 % -25.2 % -26.06 % -12.77 %
Y / Y Cash & cash equivalent TTM Growth -7.74 % -14.1 % -27.91 % -24.43 % -18 %
Quick Ratio TTM 8.59 9.76 8.22 7.79 7.46
Total Ranking TTM # 540 # 4158 # 4256 # 291 # 4300
Seq. Current Liabilities TTM Growth 16.76 % -12.4 % -10.18 % -12.76 % -1.81 %
Seq. Cash & cash equivalent TTM Growth 2.82 % 4.02 % -5.24 % -8.98 % -4.27 %

Quick ratio ranking by company, industry and sector >> Back to KIN Financial Strength Comparisons >> Go to Compare KIN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2021 to $11.26 millions, cumulative Quick Ratio decreased to 8.59 below the Kindred Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 225 other companies have achieved higher Quick Ratio than Kindred Biosciences Inc . While Quick Ratio overall ranking has improved so far to 540, from total ranking during the twelve months ending first quarter 2021 at 4158.

Explain Quick Ratio?
How much Cash & cash equivalents KIN´s has?
What are KIN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 226
Healthcare Sector # 339
Within the Market # 540


trailing twelve months Quick Ratio Statistics
High Average Low
29.32 15.06 7.46
(Jun 30 2016)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2021 MRQ Cash & cash equivalentJun 30 2021 MRQ Current Liabilities
Oncternal Therapeutics Inc   18.07 $ 103.663  Millions$ 5.738  Millions
Viking Therapeutics Inc   18.01 $ 228.258  Millions$ 12.673  Millions
Processa Pharmaceuticals Inc   17.94 $ 20.831  Millions$ 1.161  Millions
Oragenics Inc   17.91 $ 34.575  Millions$ 1.930  Millions
Climb Bio Inc   17.81 $ 99.482  Millions$ 5.586  Millions
Calcimedica Inc   17.77 $ 73.586  Millions$ 4.141  Millions
Enveric Biosciences Inc   17.66 $ 20.618  Millions$ 1.168  Millions
Otonomy Inc   17.65 $ 97.878  Millions$ 5.546  Millions
Rain Enhancement Technologies Holdco Inc   17.64 $ 164.647  Millions$ 9.336  Millions
Xenon Pharmaceuticals Inc   17.39 $ 260.523  Millions$ 14.982  Millions
Immunome Inc   17.21 $ 59.829  Millions$ 3.477  Millions
Benitec Biopharma Inc   17.11 $ 19.778  Millions$ 1.156  Millions
Atrium Therapeutics Inc   17.10 $ 279.458  Millions$ 16.338  Millions
Arca Biopharma Inc  17.10 $ 63.197  Millions$ 3.695  Millions
Crinetics Pharmaceuticals Inc   17.10 $ 203.762  Millions$ 11.919  Millions
Forte Biosciences Inc   17.06 $ 50.795  Millions$ 2.978  Millions
Ayala Pharmaceuticals Inc   17.01 $ 45.257  Millions$ 2.660  Millions
Protokinetix Incorporated  16.92 $ 0.085  Millions$ 0.005  Millions
Uniqure N v   16.79 $ 677.330  Millions$ 40.343  Millions
Rocket Pharmaceuticals Inc   16.78 $ 426.830  Millions$ 25.444  Millions
Whitehawk Therapeutics Inc   16.75 $ 36.816  Millions$ 2.198  Millions
Minerva Neurosciences Inc   16.70 $ 74.215  Millions$ 4.444  Millions
Allakos Inc   16.46 $ 559.695  Millions$ 33.998  Millions
Hepion Pharmaceuticals Inc   16.15 $ 110.091  Millions$ 6.816  Millions
Satsuma Pharmaceuticals Inc   16.00 $ 121.164  Millions$ 7.575  Millions
Cogent Biosciences Inc   15.94 $ 218.105  Millions$ 13.681  Millions
Lumos Pharma Inc   15.89 $ 107.696  Millions$ 6.777  Millions
Silo Pharma Inc  15.72 $ 4.151  Millions$ 0.264  Millions
Tyme Technologies Inc.  15.68 $ 72.623  Millions$ 4.632  Millions
Vistagen Therapeutics Inc   15.60 $ 97.777  Millions$ 6.267  Millions

Date modified: 2026-08-29T17:19:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.